诚达药业：接受信达证券等投资者调研

Group 1 - Chengda Pharmaceutical announced that on January 14, 2026, it will accept an investor survey conducted by Cinda Securities, with participation from the company's director and general manager, Lu Gang, who will address investor inquiries [1] Group 2 - Haili Biological's acquisition of a company has seen a ninefold increase in value, yet the valuation has halved over the past eight months, raising concerns as its largest client is a company that has not yet been established [1]